Research map: Development of a simplified population pharmacokinetic–pharmacodynamic framework for exposure-informed risk stratification of neutropenia during amrubicin treatment

Back to the article

Papers in this map

  1. Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs · Lena E. Friberg · 2002 · 543 citations · Cited by this paper
  2. Deciphering autophagy-metabolism interactions in cancer drug resistance: a comprehensive review · 2026 · Related
  3. Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia · William Edward Evans · 1998 · 502 citations · Cited by this paper
  4. Pharmacokinetic and pharmacogenomic profile of capecitabine and oxaliplatin in a patient with gastric cancer undergoing hemodialysis: a case report · 2026 · Related
  5. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. · René Bruno · 1998 · 424 citations · Cited by this paper
  6. Temozolomide resistance in glioma: aligning target discovery with clinically achievable CNS exposures and translational delivery strategies · 2026 · Related
  7. Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia · William E. Evans · 1986 · 394 citations · Cited by this paper
  8. Physiologically based pharmacokinetic modeling of granisetron for optimizing antiemetic therapy in patients with cancer: multi-route pharmacokinetic characterization and target-site exposure prediction · 2026 · Related
  9. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. · Duncan Ian Jodrell · 1992 · 385 citations · Cited by this paper
  10. Transfer of trastuzumab and pertuzumab into human breast milk: a case report · 2026 · Related
  11. Marrow Transplantation for Chronic Myeloid Leukemia: The Influence of Plasma Busulfan Levels on the Outcome of Transplantation · John T. Slattery · 1997 · 354 citations · Cited by this paper
  12. Synergistic anti-tumor activity of andrographolide and gemcitabine in intrahepatic cholangiocarcinoma through inhibition of RRM2 and the JAK/STAT3 pathway · 2026 · Related
  13. Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer · Erick C. Gamelin · 2008 · 347 citations · Cited by this paper
  14. Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis · 2026 · Related
  15. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials · Massimo Di Maïo · 2005 · 237 citations · Cited by this paper
  16. Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life · 2026 · Related
  17. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia · Börje S. Andersson · 2002 · 228 citations · Cited by this paper
  18. Antibody–drug conjugates in colorectal cancer: molecular design, preclinical advances, and translational challenges · 2026 · Related
  19. Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer · Federico Innocenti · 2014 · 143 citations · Cited by this paper
  20. The potential and promise of natural antioxidants as epigenetic modulators in oral squamous cell carcinoma · 2026 · Related
  21. Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy · Jan Hendrik Beumer · 2018 · 131 citations · Cited by this paper
  22. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC) · Markus Joerger · 2016 · 90 citations · Cited by this paper
  23. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03 · Yusuke Kishida · 2009 · 89 citations · Cited by this paper
  24. Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes · Andrew R. Rezvani · 2013 · 84 citations · Cited by this paper
  25. Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study · Frederike K. Engels · 2011 · 79 citations · Cited by this paper
  26. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy · Michelle A. Rudek · 2004 · 71 citations · Cited by this paper
  27. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model · Angelica Linnea Quartino · 2010 · 58 citations · Cited by this paper
  28. Randomized study of individualized pharmacokinetically‐guided dosing of paclitaxel compared with body‐surface area dosing in Chinese patients with advanced non‐small cell lung cancer · Jie Zhang · 2019 · 39 citations · Cited by this paper
  29. Standard Error of Empirical Bayes Estimate in NONMEM® VI · Dong‐Woo Kang · 2012 · 30 citations · Cited by this paper
  30. Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area · Cheng Xu · 2017 · 12 citations · Cited by this paper
  31. Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring · Joaquim Monteiro · 2025 · 9 citations · Cited by this paper
  32. Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies · Apolline Lefèvre · 2025 · 5 citations · Cited by this paper
  33. Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer · Yoshinori Makino · 2019 · 4 citations · Cited by this paper
  34. Model‐based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer · Yue Zhao · 2024 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)